GSK (LSE:GSK) Poised for Growth with Strong Sales, Strategic …
WEB20 hours ago · GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a robust 13% sales growth and strategic innovations in R&D, contrasted with ...
GSK announces positive topline data on co-administration of …
WEBThe Control group received GSK’s RSV vaccine at day 31. 1,2 RZV second dose was administered at day 61 for both groups. 1,2 The primary endpoint was the non-inferiority of the humoral immune responses to GSK’s RSV vaccine and RZV when co-administered compared to when administered at separate visits. 1,2 Key secondary endpoints included ...
GSK posts trial win for RSV, shingles shots (NYSE:GSK)
WEB14 hours ago · GSK posts late-stage trial win for co-administered RSV and shingles vaccines Sep. 18, 2024 2:48 PM ET GSK plc (GSK) Stock By: Dulan Lokuwithana , SA News Editor Play ( 1min )
GSK Reports Positive Data From Co-administration Of RSV And …
WEB19 hours ago · RTTNews. Sep. 18, 2024, 09:33 AM. (RTTNews) - GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity ...
Press releases - GSK
WEBBrowse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
GSK's RSV vaccine meets main goal when co-administered with …
WEB21 hours ago · British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years ...
GSK makes a strong start to 2024 with improving outlook for the …
WEBMay 1, 2024 · Now expect 2024 turnover growth towards the upper part of 5% to 7% range; Core operating profit growth of 9% to 11% (previously 7% to 10%); Core EPS growth of 8% to 10% (previously 6% to 9%) Dividend declared of 15p for …
GSK News
WEBStay updated on the latest news from GSK, a global healthcare company with innovative medicines, vaccines and consumer products.
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first RSV vaccine for older ...
GSK delivers strong 2023 performance and upgrades growth …
WEBJan 31, 2024 · Broad-based performance drives sales, profits and earnings growth: Total 2023 sales £30.3 billion +5% and +14% ex COVID. Vaccines sales +25%, +24% ex COVID. Shingrix £3.4 billion +17%, Arexvy £1.2 billion.
Skip to content